A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

Asthma affects millions of people worldwide, and adult women experience the condition more frequently—and often more severely ...

New research reveals hidden inflammation chemicals in asthma that rise with symptom severity and may allow earlier, simpler ...

A new study has confirmed that male and female lungs are "wired differently" at the molecular level, providing further ...

By Dennis Thompson HealthDay ReporterMONDAY, Feb. 9, 2026 (HealthDay News) — Children are more likely to develop asthma if they are raised in damp homes or neighborhoods with heavy air pollution, a ...

Estimated annual cost of asthma management totaled $2,181 per SMART-prescribed patient compared with $2,235 with traditional ...

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.

The clinical-stage biotechnology company said the Phase 2 Valiant clinical trial, evaluating verekitug in adults with severe asthma, showed that verekitug reduced asthma attacks and improved lung ...

Researchers and doctors are beginning to modernize asthma treatment using innovative therapies. Asthma is a common, chronic and treatable lung disease that touches nearly every family in America. It ...

Paediatric respiratory specialist Dr Cara Bossley provides an overview of management of wheeze in preschool children ...

A lingering cough is often blamed on asthma or past tuberculosis, but experts warn that a lesser-known fungal lung disease ...

Dr. Douglas Lotz steps in as Interim CEO, with a clear focus on patient-first care. Building on a legacy of trusted ...